Received Mar 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
Bell's Palsy, most extreme symptoms dissipated after two months, but patient continue to have feelings of numbness on the right side of face; This spontaneous case was reported by a patient and describes the occurrence of BELL'S PALSY (Bell's Palsy, most extreme symptoms dissipated after two months, but patient continue to have feelings of numbness on the right side of face) in a 54-year-old male patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) for COVID-19 prophylaxis. No Medical History information was reported. On 13-Sep-2024, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use) 1 dosage form. On 17-Sep-2024, after starting mRNA-1273.712 (SPIKEVAX 2024-2025 PFS), the patient experienced BELL'S PALSY (Bell's Palsy, most extreme symptoms dissipated after two months, but patient continue to have feelings of numbness on the right side of face) (seriousness criterion medically significant). At the time of the report, BELL'S PALSY (Bell's Palsy, most extreme symptoms dissipated after two months, but patient continue to have feelings of numbness on the right side of face) had not resolved. For mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use), the reporter did not provide any causality assessments. No concomitant medication was reported. It was unknown if the patient experienced any additional symptoms/events. No treatment information was reported.; Reporter's Comments: The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.